COMBINATORIAL CHEMISTRY TO DISCOVER NOVEL SWEETENERS

描述：（改编自申请人摘要） 用于各种加工食品的致龋和无热量甜味剂 和饮料产品等待未来的发现。 这些甜味剂将 对市场和防止糖的产生巨大的影响- 相关疾病，如龋齿和糖尿病。 患者 通过控制饮食碳水化合物的摄入， 品尝合成甜味剂是显而易见的。 第一阶段STTR项目将 评估针对甜胍的单克隆抗体的能力， 筛选化合物的组合肽模拟物文库， 具有甜味剂活性。 一种基于抗体的 “人工受体”的发现新的甜味化合物是 这个项目独一无二的。 该项目有三个里程碑：（1）开发有偏组合 用单克隆抗体鉴定新配体的拟肽文库 抗甜味剂抗体：（2）荧光偏振免疫测定 识别拟肽配体;（3）“第二迭代”的产生 用于进一步表征的候选化合物的偏向文库。 每个里程碑将由申请人独立完成 然而，无论是组织还是研究组织， 项目需要双方的合作和伙伴关系。 的 该STTR提案的目标与 美国国立卫生研究院龋齿、营养和氟化物项目 牙科研究（NIDR）和国家牙科研究所的使命 糖尿病、消化和肾脏疾病（NIDDK）。 拟议商业应用：不可用

DESCRIPTION: (Adapted from the applicant's abstract) Novel non- cariogenic and non-caloric sweeteners for a variety of processed food and beverage products await future discoveries. Such sweeteners will have a dramatic impact on the marketplace and prevention of sugar- associated diseases, such as dental caries and diabetes. For patients with regulated dietary carbohydrate intake, the rationale for good- tasting synthetic sweeteners is obvious. This Phase I STTR Project will assess the ability of monoclonal antibodies made to sweet guanidines to screen combinatorial peptidomimetic libraries of compounds that may possess sweetener activity. The deployment of an antibody-based "Artificial Receptor" for the discovery of novel sweet compounds is unique to this project. The project has three milestones: (1) Develop biased combinatorial peptidomimetic libraries to identify novel ligands using monoclonal anti-sweetener antibodies: (2) Fluorescence polarization immunoassays to identify peptidomimetic ligands; (3) Generation of "second-iteration" biased libraries of candidate compounds for further characterization. Each Milestone will be carried out independently by the applicant organization or the research organization, however, the success of the project requires cooperation and partnership between both parties. The objective of this STTR proposal has high program relevance to the Caries, Nutrition and Fluoride Program of the National Institute of Dental Research (NIDR) and the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE